AstraZeneca Aktie News

AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises.

If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.

At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.

AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufacturing investment in the country.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company's previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca's largest s...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan, which expects earnings to come in modestly ahead of market expectations and guidance for 2026 to underpin confidence in the growth outlook. The US bank forecasts fourth-quarter revenues of $15.5 billion, representing 2% growth at constant exch...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology dru...

With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.